In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d.
Ann Intern Med
; 175(2): JC17, 2022 02.
Article
in English
| MEDLINE | ID: covidwho-1716078
ABSTRACT
SOURCE CITATION Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19 the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;1811612-20. 34617959.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Venous Thromboembolism
/
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Ann Intern Med
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS